Lisa Pompa Email & Phone Number

Norfolk, Virginia Area

• Launched first ever gene therapy (Luxturna) an inherited orphan disease in the National, Regional, and Blue’s Commercial payer space strategizing with C-suite level stakeholders to prepare for payment and delivery on.
• Achieved over 90% published reasonable medical policy, addressing access issues by partnering with Medical Affairs to reverse any initial negative policies.
• Executed on adoptions of an “first of its kind” innovative payment model that will serve as a benchmark for gene therapy moving forward. Completing pricing agreements with select payers.
• Led the Blue’s National Payer Strategy both internally with the Commercial Payer team and externally with implementation of Innovative Payment Model and Value Based Agreements as it relates to Blue Card and the.
• Selected to present Gene Therapy Payment and Delivery Options at quarterly BCBS National Council of Physician and Pharmacist Executive Meeting attended by top pharmacy executives of 36 Blues plans.
• Facilitated Executive Exchange between National Payers and Spark Executive team to identify strategic partnerships and long-term collaboration opportunities.

Selected to replace 1 of 4 National Account Directors to ensure optimal access for anti-VEGF EYLEA in National and select Regional healthcare payers. Primary accounts include UHC, Optum Rx, Prime Therapeutics, HCSC, Magellan Rx and BCBS FL, LA, AR, AL and TN. Activity includes problem solving reimbursement challenges for high cost buy & bill biologic.

Mid-Atlantic States (MD, DC, VA, NC, SC, KY)

Recruited as 1 of 19 RAMs nationally (now 1 of 9) to the newly created commercial division to maximize share growth and attain access for Kalydeco (orphan Cystic Fibrosis drug) and Incivek (Hepatitis C) within Commercial, Managed Medicaid, FFS, Medicare Part D, Corrections, and Specialty Pharmacy accounts. Devise and execute pull-through strategies to.

Retained subsequent to Wyeth merger with Pfizer to negotiate contracts and secure formulary access, coverage, and reimbursement for full portfolio of biologics / small molecule products, including Lipitor, Lyrica, Celebrex, Enbrel, Premarin, Viagra, Genotropin, Relpax, Pristiq, Aricept, and Chantix with Commercial, Managed Medicaid, ACO, and Medicare Part.

Appointed to formulate and execute the business development, marketing, contracting / contract compliance, and rebate strategies to achieve formulary access for Wyeth products within regional MCO and federal government (DOD / VA) accounts. Represented large product portfolio, including Enbrel, Protonix, Effexor XR, Altace, Zosyn, and Enbrel. Interfaced.

Norfolk, Virginia Area

Promoted subsequent to unparalleled success in previous position, charged with promoting and selling Wyeth’s hospital products (IV antibiotics, PPIs, antidepressants, TNF inhibitors, and cardiovascular) in medical centers, community hospitals, and DOD / VA military facilities in the Mid-Atlantic States. Attained formulary access and formed trusted.